Last reviewed · How we verify
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.
Details
| Lead sponsor | Samus Therapeutics, Inc. |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 11 |
| Start date | Mon Aug 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Nov 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera Myelofibrosis (Post-PV MF)
- Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
- PU-H71
Countries
United States